Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy

Objectives Myositis-specific autoantibodies (MSAs) are useful tools for identifying clinically homogeneous subsets and predicting prognosis of patients with idiopathic inflammatory myopathies (IIM) including polymyositis (PM) and dermatomyositis (DM). Recent studies have shown that anti-NXP2 antibody (Ab) is a major MSA in juvenile dermatomyositis (JDM). In this study the frequencies and clinical associations of anti-NXP2 Ab were evaluated in adult patients with IIM. Methods Clinical data and serum samples were collected from 507 adult Japanese patients with IIM (445 with DM and 62 with PM). Eleven patients with JDM, 108 with systemic lupus erythematosus, 433 with systemic sclerosis and 124 with idiopathic pulmonary fibrosis were assessed as disease controls. Serum was examined for anti-NXP2 Ab by immunoprecipitation and western blotting using polyclonal anti-NXP2 Ab. Results Seven patients (1.6%) with adult DM and one (1.6%) with adult PM were positive for anti-NXP2 Ab. Except for two patients with JDM, none of the disease controls were positive for this autoantibody. Among eight adult patients with IIM, three had internal malignancies within 3 years of diagnosis of IIM. Another patient with DM also had a metastatic cancer at the diagnosis. All of the carcinomas were at an advanced stage (stage IIIb–IV). Conclusions While less common than in juvenile IIM, anti-NXP2 Ab was found in adult IIM. Anti-NXP2 Ab may be associated with adult IIM with malignancy.

[1]  M. Fujimoto,et al.  Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. , 2012, Arthritis and rheumatism.

[2]  I. Lundberg,et al.  Pathogenesis, classification and treatment of inflammatory myopathies , 2011, Nature Reviews Rheumatology.

[3]  M. Fujimoto,et al.  Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. , 2011, Archives of dermatology.

[4]  L. Christopher‐Stine Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein , 2010 .

[5]  J. Vencovský,et al.  Clinical Associations Of Anti-p140 Autoantibodies In Adult Myositis , 2010 .

[6]  M. Barton,et al.  Regulation of p53: TRIM24 enters the RING , 2009, Cell cycle.

[7]  E. Taraldsrud,et al.  [Myositis-specific autoantibodies]. , 2009, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[8]  T. Fujita,et al.  RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. , 2009, Arthritis and rheumatism.

[9]  N. McHugh,et al.  Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. , 2009, Rheumatology.

[10]  L. Wedderburn,et al.  Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis , 2009, Arthritis and rheumatism.

[11]  L. Wedderburn,et al.  Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. , 2007, Rheumatology.

[12]  A. Zinn,et al.  Dynamic regulation of p53 subnuclear localization and senescence by MORC3. , 2007, Molecular biology of the cell.

[13]  W. Ollier,et al.  The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis , 2007, Annals of the rheumatic diseases.

[14]  THE CLINICAL ASSOCIATIONS , 2007 .

[15]  M. Fujimoto,et al.  Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. , 2007, Rheumatology.

[16]  I. Targoff,et al.  A novel autoantibody to a 155-kd protein is associated with dermatomyositis. , 2006, Arthritis and rheumatism.

[17]  R. Sontheimer Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? , 2002, Journal of the American Academy of Dermatology.

[18]  C. Oddis,et al.  Clinical and serological characterization of the anti-MJ antibody in childhood myositis , 1997 .

[19]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[20]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .